Skip to content
Esta página está disponible en españolCambiar →
GestorLensSign up

Core Scientific (CORZ): which funds own it

Information Technology →Data as of Jun 30, 2026 (Q2 2026) · updated on Nov 5, 2026

A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.

Follow CORZ for free
Share

Sections with a free account

13 concentrated managers hold it (+3 vs last quarter) with a median weight of 0.5%. 2 officers or directors bought in 6 months.

Who owns Core Scientific?

Holders that filed a Schedule 13D or 13G with the SEC for owning more than 5% of the shares: BlackRock (13G/A filed Jul 16, 2025), MFN Partners (13G filed Oct 28, 2026), Jericho Capital Asset Management (13G filed Aug 14, 2026), Citadel Securities GP (13G filed Aug 5, 2026) and Jane Street Group (13G/A filed Aug 12, 2026). As of Jun 30, 2026, the largest holders reported on Form 13F were BlackRock (28.1 million shares), Situational Awareness (26.0 million shares) and Jericho Capital Asset Management (22.9 million shares).

Which institutions hold the most Core Scientific shares?

Per Form 13F filings as of Jun 30, 2026:

  1. 1. BlackRock: 28.1 million shares
  2. 2. Situational Awareness: 26.0 million shares
  3. 3. Jericho Capital Asset Management: 22.9 million shares
  4. 4. Vanguard Portfolio Management: 18.7 million shares
  5. 5. UBS Group: 15.9 million shares
  6. 6. Vanguard Capital Management: 13.8 million shares
  7. 7. Two Sigma Investments: 10.3 million shares
  8. 8. Value Aligned Research Advisors: 9.2 million shares
  9. 9. Two Seas Capital: 9.0 million shares
  10. 10. Geode Capital Management: 8.5 million shares

Sources:13G/A by BlackRock (Jul 16, 2025) ↗13G by MFN Partners (Oct 28, 2026) ↗13G by Jericho Capital Asset Management (Aug 14, 2026) ↗13G by Citadel Securities GP (Aug 5, 2026) ↗13G/A by Jane Street Group (Aug 12, 2026) ↗All of the company's proxy statements on EDGAR ↗

We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.

Core Scientific revenue

Core Scientific reported annual revenue of $319.0 million for fiscal year 2025 (year ended December 31, 2025), according to its Form 10-K filed with the SEC (XBRL data).

Well-known investors holding it

Howard Marks 13F (Q2 2026)Chase Coleman 13F (Q2 2026)Dan Loeb 13F (Q2 2026)George Soros 13F (Q2 2026)

Concentrated managers
13
All 13F: 414
Consensus
40/100
across 13 concentrated managersRanks by accumulation, portfolio weight and number of managers; it does not say more are buying than selling.
Price at Jun 30, 2026 (per 13F)
$25.59
+71.1% in the quarter · reported value ÷ shares, not the quote · See current quote ↗

Quarter flow (concentrated managers)

Change in managers (10 → 13): 7 opened · 4 exited = +3

Net flow in the quarter: +$291M (+11.4 M shares) · bought $441M and sold $149MShares concentrated managers added minus those they cut, valued at the 13F quarter-end implied price, not each trade's price. It is a different measure from the change in managers: the two can have opposite signs.

The set of concentrated managers changed between quarters: with the set as it was then, 11 held it last quarter (the chart point); with today's set, 10 (the base for the change).

Concentrated managers holding it

Up to 15, sorted by position value. The percentage is the weight in each manager's portfolio.

Other relevant holders

Filers with $100M or more in the stock that do not count as concentrated managers because of their type: they are left out of the counts, the consensus and the accumulation.

Largest holders of CORZ (all 13F filers)

The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.

Well-known investors with options on this stock

The 13F does not say whether the option is bought or written, nor its strike or expiry. It may be a hedge. It is not added to the portfolio. The figure is the value of the underlying shares (notional), not the premium paid. Well-known investors only: among all 13F filers, most options belong to market makers.

Fundamentals

12-month figures to Jun 30, 2026.

Profitability
Operating margin
-127.4%
Net margin
—
ROE
—
Growth
Revenue (TTM)
$440M
Revenue growth
26.4%
Net income (TTM)
$-1.4 bn
Balance sheet
Quality vs sector
—

Bank, insurer or other financial company: we do not show net debt / EBITDA or free cash flow. Its cash flow moves with loans and the investment portfolio, and its debt is part of the business: those figures do not read as they do for an industrial company.

Figures from the statements the company filed with the SEC (10-K, 10-Q). Free cash flow = operating cash flow − capital expenditures; empty if the company does not report capex. “Quality vs sector”: 0 to 100, the average of its percentiles in ROE, operating margin, free-cash-flow margin, revenue and earnings growth and net debt / EBITDA (at least 3 needed) against companies in its sector above $300M. How each figure is calculated

Shares outstanding: buybacks and dilution

Diluted shares by fiscal year (split-adjusted)

2025: 318.1 M

379.9 M0
20212025
1 year
+24.3%
3 years
−6.6%
5 years
no data
Buybacks (FY 2025)
no data
Share issuance
$0
Stock-based compensation
$98.2M30.8% of revenue
Dividends paid
no data

From the statements the company filed with the SEC (10-K). The change compares average diluted shares of each fiscal year, on today's basis: negative = it bought back more than it issued; positive = dilution. “No data” = the company does not report that item under a tag we can read; it does not mean zero.

Earnings quality and debt

Operating cash flow ÷ net income (12 months)
no datanot calculated with negative net income

Bank or insurer: debt ratios do not apply.

From the figures the company filed with the SEC. Cash flow over net income near or above 1 means earnings are collected in cash; far below, that part is accounting. Coverage says how many times operating income pays the latest fiscal year's interest. Maturities come from the debt note of the latest annual report, counted from its closing date. “No data” never means zero.

Insiders (Form 4)

Officers and directors who bought (6 m)
2
Amount (6 m)
$342K
CEO/CFO bought (12 m)
No

10% owners who bought (6 m): 0

Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.

Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →

Above 5% (13D/13G)

Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.

This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.

Above 5% over time (13D/13G)

Each holder with its filings in order. History since December 2024.

Flagged material events (8-K)

  • Mar 2, 2026Seriousfiling ↗

    Previously issued financial statements can no longer be relied on (Item 4.02)

    «Core Scientific Announces Fourth Quarter Fiscal Year 2025 Results»

  • Jul 29, 2026Routinefiling ↗

    Change in directors or officers (Item 5.02)

  • Jul 28, 2026Routinefiling ↗

    Unregistered sale of equity securities (Item 3.02)

  • May 26, 2026Routinefiling ↗

    Change in directors or officers (Item 5.02)

  • May 5, 2026Routinefiling ↗

    Change in directors or officers (Item 5.02)

  • Feb 19, 2026Routinefiling ↗

    Change in directors or officers (Item 5.02)

  • Feb 18, 2026Routinefiling ↗

    Change in directors or officers (Item 5.02)

Alert items the company itself flagged in its 8-K filings with the SEC, most serious first. It is the form's label, with no interpretation from us: Item 5.02 covers routine appointments as well as a chief executive's departure; open the filing. The quoted headline is the original press release's.

All material events (8-K)

Earnings, agreements, financing, management changes and announcements from the last year, with a filter by type and a link to each filing.

Other Information Technology stocks in managers' portfolios

Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.

All of Information Technology →

Follow CORZ for free

If someone reports a 5%+ stake, we email you (if you turn it on). And when you come back, see whether concentrated managers got in or out. No credit card.

Follow CORZ